A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
This study was not conducted in the United States. Many people with type 2 diabetes also have
high cholesterol levels. The purpose of this study was to evaluate the effects of
vildagliptin, an unapproved drug, on blood lipid measures such as triglycerides and
cholesterol in people with type 2 diabetes.